Processa Pharmaceuticals (PCSA) Other Working Capital Changes (2019 - 2025)
Processa Pharmaceuticals' (PCSA) quarterly Other Working Capital Changes came in at -$21832.0 in Q3 2025, down 6.25% YoY from -$23287.2 in Q3 2024, and up 4.08% on a QoQ basis from -$22761.0 in Q2 2025.
Processa Pharmaceuticals (PCSA) Other Working Capital Changes (2019 - 2025) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 7 years of Other Working Capital Changes data on file, last reported at -$21832.0 in Q3 2025.
- Quarterly Other Working Capital Changes fell 6.25% year-over-year to -$21832.0 in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$66905.0 (up 20.02% YoY) and the FY2025 annual result came in at -$66905.0, up 20.02% from the prior year.
- Other Working Capital Changes climbed to -$21832.0 in Q3 2025, from -$22761.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $1.0 million in Q2 2024 to a low of -$615839.0 in Q2 2025.
- A 5-year average of -$50479.6 and a median of -$68665.0 in 2024 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2021 — Other Working Capital Changes declined 24.01% — and 2022, when it rose 19.77%.
- Tracing PCSA's Other Working Capital Changes over 5 years: stood at -$23079.0 in 2021, then gained by 19.77% to -$18517.0 in 2022, then declined by 13.23% to -$20967.0 in 2023, then slipped by 4.32% to -$21873.0 in 2024, then grew by 0.19% to -$21832.0 in 2025.
- The last three Other Working Capital Changes figures came in at -$21832.0 (Q3 2025), -$22761.0 (Q2 2025), and -$22312.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Processa Pharmaceuticals | 5.93 Mn | 5.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -21,832.00 |
| Sep 30, 2025 | -21,832.00 |
| Sep 30, 2025 | -21,832.00 |
| Jun 30, 2025 | -22,761.00 |
| Jun 30, 2025 | -22,761.00 |
| Jun 30, 2025 | -22,761.00 |
| Mar 31, 2025 | -22,312.00 |
| Mar 31, 2025 | -22,312.00 |
| Mar 31, 2025 | -22,312.00 |
| Dec 31, 2024 | -21,873.00 |
| Dec 31, 2024 | -21,873.00 |
| Dec 31, 2024 | -21,873.00 |
| Sep 30, 2024 | -20,548.00 |
| Sep 30, 2024 | -20,548.00 |
| Sep 30, 2024 | -20,548.00 |
| Jun 30, 2024 | -20,145.00 |
| Jun 30, 2024 | -20,145.00 |
| Jun 30, 2024 | -20,145.00 |
| Mar 31, 2024 | -21,083.00 |
| Mar 31, 2024 | -21,083.00 |